SEC Comment Letter 0000000000-23-000211 to CollPlant Biotechnologies Ltd (CLGN)
CollPlant Biotechnologies Ltd
Date: Jan. 6, 2023 · CIK: 0001631487 · Accession: 0000000000-23-000211
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269087
Letter
United States securities and exchange commission logo January 6, 2023 Yehiel Tal Chief Executive Officer CollPlant Biotechnologies Ltd 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel Re:CollPlant Biotechnologies Ltd Registration Statement on Form F-3 Filed December 30, 2022 File No. 333-269087 Dear Yehiel Tal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Nimitz 202-551-5831 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
United States securities and exchange commission logo
January 6, 2023
Yehiel Tal
Chief Executive Officer
CollPlant Biotechnologies Ltd
4 Oppenheimer, Weizmann Science Park
Rehovot 7670104, Israel
Re:CollPlant Biotechnologies Ltd
Registration Statement on Form F-3
Filed December 30, 2022
File No. 333-269087
Dear Yehiel Tal:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jordan Nimitz 202-551-5831 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services